**Common Drug Review**

**Submission Status**

### Product:
Uloric

### Generic Name:
Febuxostat

### Manufacturer:
Takeda Canada Inc.

### Indication:
Gout

### Submission Type:
Initial

### Date Submission Received:
2010-Oct-27

### Date NOC Issued:
2010-Sep-22

### Targeted CEDAC Meeting:
2011-Mar-23

### Priority Review Granted:
Not Requested

<table>
<thead>
<tr>
<th>Phase</th>
<th>Target Time (Business Days)</th>
<th>Target Date **</th>
<th>Actual CDR Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Submission deemed complete</td>
<td>5</td>
<td>2010-Nov-03</td>
<td>2010-Nov-04</td>
</tr>
<tr>
<td>2</td>
<td>Patient group input submission received</td>
<td></td>
<td>2010-Nov-17</td>
<td>2010-Nov-17</td>
</tr>
<tr>
<td>3</td>
<td>CADTH Reviewers’ Reports sent to Manufacturer</td>
<td>45</td>
<td>2011-Jan-25</td>
<td>2011-Jan-28</td>
</tr>
<tr>
<td>4</td>
<td>Comments from Manufacturer on Reviewers’ Reports Received by CADTH</td>
<td>7</td>
<td>2011-Feb-03</td>
<td>2011-Feb-08</td>
</tr>
<tr>
<td>5</td>
<td>CEDAC Meeting</td>
<td></td>
<td>2011-Mar-23</td>
<td>2011-Mar-23</td>
</tr>
<tr>
<td>6</td>
<td>CEDAC Recommendation *** Sent to Drug Plans, ACP and Manufacturer</td>
<td>5 to 7</td>
<td>2011-Mar-30</td>
<td>2011-Apr-01</td>
</tr>
<tr>
<td>8 (a)</td>
<td>Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)</td>
<td>5</td>
<td>2011-Apr-20</td>
<td>2011-Apr-25</td>
</tr>
<tr>
<td>8 (b)</td>
<td>Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 (c)</td>
<td>Placed on CEDAC Agenda For Reconsideration (At Manufacturer’s request)</td>
<td>25 Depends on Meeting Dates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Final Recommendation sent to Drug Plans, ACP, and Manufacturer</td>
<td></td>
<td></td>
<td>5</td>
</tr>
</tbody>
</table>

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of [www.cadth.ca](http://www.cadth.ca) for more details.

** The Formulary review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on [www.cadth.ca](http://www.cadth.ca).

*** The Procedure for Common Drug Review, section 8.3.3a, states “…the CEDAC recommendation will be sent to the Manufacturer, ACP and to the drug plans within five (5) to seven (7) business days following the CEDAC meeting…”: The original target date is based on five (5) business days.

**** The Recommendation is held in confidence and not acted upon until after CADTH has issued the notice of Final Recommendation. This submission status report reflects updates as of Thursday noon.

2011-May-06